Novadip Biosciences is a biopharmaceutical company that uses adipose-derived stem cells within a 3-dimensional extracellular matrix to create innovative treatments for severe bone healing disorders. Their lead product, NVD-001, is a 3D natural bone implant that replaces and repairs large bone defects. Novadip closed a EUR 28 million Series A Round in September 2015 to advance their breakthrough cell therapy pipeline.